Lannett Company pharmaceutical manufacturing facility in Seymour, Indiana.
Aurobindo Pharma’s US subsidiary has received crucial approval from the Federal Trade Commission (FTC) for its proposed $250 million acquisition of Lannett Company. This significant development paves the way for the transaction to be finalized, with an expected completion date by June 2026.
The acquisition is poised to strategically bolster Aurobindo’s existing portfolio, particularly in the complex generics and controlled substances segments. Furthermore, the integration of Lannett’s manufacturing facility in Indiana is anticipated to significantly enhance Aurobindo’s operational capabilities within the United States.
Analysts anticipate that the deal will provide an immediate positive impact on Aurobindo’s earnings per share, underscoring the financial rationale behind the strategic move. The FTC’s clearance is a key hurdle overcome, bringing Aurobindo closer to expanding its market presence and product offerings in the competitive US pharmaceutical landscape.
About the Author
